NASDAQ:SYRS - Syros Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Syros Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $7.97 -0.24 (-2.92 %) (As of 01/24/2020 09:17 AM ET) Add Compare Today's Range$7.93Now: $7.97▼$8.4450-Day Range$4.52MA: $6.77▼$9.2152-Week Range$4.45Now: $7.97▼$11.93Volume243,273 shsAverage Volume333,844 shsMarket Capitalization$338.25 millionP/E RatioN/ADividend YieldN/ABeta1.59 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SYRS Previous Symbol CUSIPN/A CIK1556263 Webhttp://www.syros.com/ Phone617-744-1340Debt Debt-to-Equity Ratio0.20 Current Ratio4.92 Quick Ratio4.92Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$2.05 million Price / Sales165.00 Cash FlowN/A Price / Cash FlowN/A Book Value$2.34 per share Price / Book3.41Profitability EPS (Most Recent Fiscal Year)($1.91) Net Income$-62,280,000.00 Net Margins-3,115.38% Return on Equity-84.49% Return on Assets-60.09%Miscellaneous Employees76 Outstanding Shares42,440,000Market Cap$338.25 million Next Earnings Date3/5/2020 (Estimated) OptionableOptionable Receive SYRS News and Ratings via Email Sign-up to receive the latest news and ratings for SYRS and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:SYRS Rates by TradingView Syros Pharmaceuticals (NASDAQ:SYRS) Frequently Asked Questions What is Syros Pharmaceuticals' stock symbol? Syros Pharmaceuticals trades on the NASDAQ under the ticker symbol "SYRS." How were Syros Pharmaceuticals' earnings last quarter? Syros Pharmaceuticals Inc (NASDAQ:SYRS) released its earnings results on Tuesday, November, 12th. The company reported ($0.47) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.48) by $0.01. The firm earned $0.56 million during the quarter, compared to analyst estimates of $0.43 million. Syros Pharmaceuticals had a negative return on equity of 84.49% and a negative net margin of 3,115.38%. View Syros Pharmaceuticals' Earnings History. When is Syros Pharmaceuticals' next earnings date? Syros Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Syros Pharmaceuticals. What price target have analysts set for SYRS? 7 Wall Street analysts have issued twelve-month price targets for Syros Pharmaceuticals' stock. Their forecasts range from $9.00 to $18.00. On average, they expect Syros Pharmaceuticals' share price to reach $13.83 in the next twelve months. This suggests a possible upside of 73.6% from the stock's current price. View Analyst Price Targets for Syros Pharmaceuticals. What is the consensus analysts' recommendation for Syros Pharmaceuticals? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syros Pharmaceuticals in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Syros Pharmaceuticals. Has Syros Pharmaceuticals been receiving favorable news coverage? News stories about SYRS stock have trended very positive this week, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Syros Pharmaceuticals earned a news impact score of 3.9 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for Syros Pharmaceuticals. Are investors shorting Syros Pharmaceuticals? Syros Pharmaceuticals saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 2,340,000 shares, an increase of 30.0% from the December 15th total of 1,800,000 shares. Based on an average daily trading volume, of 470,100 shares, the days-to-cover ratio is presently 5.0 days. Approximately 7.6% of the company's shares are sold short. View Syros Pharmaceuticals' Current Options Chain. Who are some of Syros Pharmaceuticals' key competitors? Some companies that are related to Syros Pharmaceuticals include Y-mAbs Therapeutics (YMAB), Dicerna Pharmaceuticals (DRNA), TG Therapeutics (TGTX), Madrigal Pharmaceuticals (MDGL), Supernus Pharmaceuticals (SUPN), IGM Biosciences (IGMS), Athenex (ATNX), Myovant Sciences (MYOV), ZEALAND PHARMA/S (ZEAL), Opko Health (OPK), Enanta Pharmaceuticals (ENTA), Portola Pharmaceuticals (PTLA), NextCure (NXTC), Karyopharm Therapeutics (KPTI) and Rocket Pharmaceuticals (RCKT). What other stocks do shareholders of Syros Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Syros Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Zynerba Pharmaceuticals (ZYNE), Nektar Therapeutics (NKTR), Sangamo Therapeutics (SGMO), Synergy Pharmaceuticals (SGYP), TherapeuticsMD (TXMD), Avid Bioservices (CDMO), Global Blood Therapeutics (GBT), Galmed Pharmaceuticals (GLMD) and ImmunoGen (IMGN). Who are Syros Pharmaceuticals' key executives? Syros Pharmaceuticals' management team includes the folowing people: Dr. Nancy A. Simonian, Pres, CEO & Director (Age 58)Dr. Richard A. Young, Scientific Founder, Member of Scientific Advisory Board & Director (Age 65)Dr. David A. Roth, Chief Medical Officer (Age 56)Dr. Jeremy P. Springhorn, Chief Bus. Officer (Age 57)Dr. Nathanael S. Gray, Scientific Founder & Member of Scientific Advisory Board When did Syros Pharmaceuticals IPO? (SYRS) raised $60 million in an initial public offering on Thursday, June 30th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. How do I buy shares of Syros Pharmaceuticals? Shares of SYRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Syros Pharmaceuticals' stock price today? One share of SYRS stock can currently be purchased for approximately $7.97. How big of a company is Syros Pharmaceuticals? Syros Pharmaceuticals has a market capitalization of $338.25 million and generates $2.05 million in revenue each year. The company earns $-62,280,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis. Syros Pharmaceuticals employs 76 workers across the globe.View Additional Information About Syros Pharmaceuticals. What is Syros Pharmaceuticals' official website? The official website for Syros Pharmaceuticals is http://www.syros.com/. How can I contact Syros Pharmaceuticals? Syros Pharmaceuticals' mailing address is 620 Memorial Drive Suite 300, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-744-1340 or via email at [email protected] MarketBeat Community Rating for Syros Pharmaceuticals (NASDAQ SYRS)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 309 (Vote Outperform)Underperform Votes: 280 (Vote Underperform)Total Votes: 589MarketBeat's community ratings are surveys of what our community members think about Syros Pharmaceuticals and other stocks. Vote "Outperform" if you believe SYRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SYRS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/24/2020 by MarketBeat.com StaffFeatured Article: How is diluted EPS different from basic EPS?
